Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - atazanavir sulfate - capsule, hard - 200 milligram(s) - atazanavir

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - atazanavir sulfate, quantity: 341.69 mg (equivalent: atazanavir, qty 300 mg) - capsule, hard - excipient ingredients: crospovidone; magnesium stearate; lactose monohydrate; titanium dioxide; indigo carmine; iron oxide yellow; sorbitan monolaurate; iron oxide red; potable water; gelatin; iron oxide black; sodium lauryl sulfate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; pharmaceutical glaze; dimeticone - reyataz is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see 5.1 pharmacodynamic properties: clinical trials).

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - atazanavir sulfate - capsule, hard - 300 milligram(s) - atazanavir

Kenya - English - Pharmacy and Poisons Board

mylan laboratories limited c/o surgilinks ltd mylan laboratories limited r&d centre plot no. - atazanavir sulfate equivalent to atazanavir… - modified-release tablet - atazanavir sulfate equivalent to atazanavir 300mg… - antivirals for systemic use: protease inhibitors

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atazanavir sulfate, quantity: 341.7 mg (equivalent: atazanavir, qty 300 mg) - capsule - excipient ingredients: lactose monohydrate; sodium starch glycollate type a; purified water; hydrophobic colloidal silica anhydrous; magnesium stearate; titanium dioxide; indigo carmine; iron oxide red; gelatin; iron oxide black; sodium lauryl sulfate - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. ,this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atazanavir sulfate, quantity: 341.7 mg (equivalent: atazanavir, qty 300 mg) - capsule - excipient ingredients: hydrophobic colloidal silica anhydrous; lactose monohydrate; sodium starch glycollate type a; purified water; magnesium stearate; titanium dioxide; indigo carmine; iron oxide red; gelatin; iron oxide black; sodium lauryl sulfate - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. ,this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies

United States - English - NLM (National Library of Medicine)

laurus labs limited - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir capsules are indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and in pediatric patients 6 years of age and older weighing at least 15 kg. limitations of use: - atazanavir is not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus [see use in specific populations (8.4)] . - use of atazanavir with ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [see microbiology (12.4)] . atazanavir capsules are contraindicated: - in patients with previously demonstrated clinically significant hypersensitivity (eg, stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of atazanavir capsules [see warnings and precautions (5.2)] . - when coadministered with drugs that are highly dependent on cyp3a or ugt1a1 for clearance, and for which elevated plasma concentrations of the interact

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atazanavir sulfate, quantity: 341.7 mg (equivalent: atazanavir, qty 300 mg) - capsule - excipient ingredients: lactose monohydrate; hydrophobic colloidal silica anhydrous; purified water; sodium starch glycollate type a; magnesium stearate; titanium dioxide; indigo carmine; iron oxide red; gelatin; iron oxide black; sodium lauryl sulfate - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. ,this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - atazanavir sulfate, quantity: 341.7 mg (equivalent: atazanavir, qty 300 mg) - capsule - excipient ingredients: magnesium stearate; lactose monohydrate; sodium starch glycollate type a; hydrophobic colloidal silica anhydrous; purified water; titanium dioxide; indigo carmine; iron oxide red; gelatin; iron oxide black; sodium lauryl sulfate - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. ,this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir 150 mg - reyataz® (atazanavir) is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection for patients 3 months and older weighing at least 5 kg. limitations of use: reyataz is contraindicated: table 6 displays drugs that are contraindicated with reyataz. drug class drugs within class that are contraindicated with reyataz clinical comment alpha 1-adrenoreceptor antagonist alfuzosin potential for increased alfuzosin concentrations, which can result in hypotension. antimycobacterials rifampin rifampin substantially decreases plasma concentrations of atazanavir, which may result in loss of therapeutic effect and development of resistance. antineoplastics irinotecan atazanavir inhibits ugt1a1 and may interfere with the metabolism of irinotecan, resulting in increased irinotecan toxicities. antipsychotics lurasidone potential for serious and/or life-threatening reactions if reyataz is coadministered with ritonavir. pimozide potential for serious and/or life-threatening reactions such